The TREOCAPA trial (Prophylactic TREatment Of the duCtus Arteriosus in Preterm infants by Acetaminophen) was a pan‑European, multicentre phase II/III randomised trial that tested whether prophylactic paracetamol/acetaminophen given during the first five days of life affects survival to 36 weeks' post‑menstrual age without severe neonatal morbidities in infants born before 29 weeks' gestation. Because the original trial faced time constraints, long‑term follow‑up was not included at trial initiation despite guidance that neonatal trials should measure outcomes after discharge and ongoing debate about long‑term neonatal paracetamol exposure.
This document describes TREOCAPA Long Term (TREOCAPA‑LT), a follow‑up study set up after trial commencement to assess outcomes at two years corrected age among children enrolled in the TREOCAPA phase III trial in participating countries.
The TREOCAPA‑LT study population comprises all children who were included in the TREOCAPA phase III trial in centres from countries participating in this follow‑up. Eligible children are those who are between 23.5 and 27.5 months corrected age during the TREOCAPA‑LT study period. Clinical teams at participating centres contact families and invite a parent or guardian to complete an online, internet‑based questionnaire.
Data collection is parent‑reported via the web questionnaire; the protocol specifies use of validated instruments to assess neurodevelopmental outcome. Analysis will be performed according to the groups to which children were randomised in the original TREOCAPA RCT (intention‑to‑treat principle implied by analysis by randomisation groups as reported).
The primary outcome for TREOCAPA‑LT is cognition measured by the non‑verbal Cognitive Scale standard score from the Parent Report of Children’s Abilities‑Revised (PARCA‑R) questionnaire. The PARCA‑R is a parent‑completed measure with a standardised scoring system; one study author is affiliated with its development and standardisation as disclosed in competing interests.
Secondary outcomes include estimates of moderate to severe neurodevelopmental impairment, measures of health service use, and cost outcomes. The protocol indicates these secondary endpoints will be analysed in relation to original randomisation groups to assess potential long‑term safety and effectiveness signals following early neonatal exposure to paracetamol.
The TREOCAPA‑LT protocol received ethics committee approval in France (the study sponsor) and subsequently obtained approvals in all participating countries. The manuscript names the approving French oversight body as Comité de protection des personnes Est I of Centre hospitalier la Chartreuse in Dijon, France.
The authors confirm that all relevant ethical guidelines were followed, necessary IRB/ethics approvals were obtained, and that participant consent procedures and institutional archiving of forms were completed. The manuscript also states adherence to relevant reporting checklists where applicable.
TREOCAPA‑LT is registered on ClinicalTrials.gov with identifier NCT06064825. The protocol states that results will be published in open access journals in accordance with the funder’s regulations.
Multiple authors are professionally affiliated with INSERM; the funder is declared but the manuscript explicitly states the funder had no role in study development or protocol writing despite these affiliations.
The authors declare competing and non‑competing interests as follows: one author (SJ) is a member of the research team that developed the PARCA‑R questionnaire and its standardised scoring system; this is reported as a professional, non‑financial interest. ASM, JCR, MU, CA, VD, MD, MH, MM and JZ are affiliated with INSERM. All other authors declare no competing interests.
The authors affirm that the study complies with ethical standards, that trial registration was completed, and that patient/participant consent and institutional documentation were managed as required.
The manuscript’s Data Availability statement reports "Not applicable (no data referred to in this manuscript)," indicating no primary or follow‑up data are presented in the protocol document. The declared funder is Inserm, with MESSIDORE 2022 listed.
The source article presents the TREOCAPA‑LT protocol together with its statistical analysis plan. Analyses will compare outcomes by the randomisation groups assigned in the TREOCAPA RCT. The primary analysis focuses on the PARCA‑R non‑verbal Cognitive Scale standard score as the cognition endpoint at two years corrected age. Secondary analyses will address neurodevelopmental impairment categories, health service utilisation, and cost measures. Specific statistical methods, sample size or power calculations, and detailed analysis procedures are described in the statistical analysis plan portion of the protocol as reported in the source document.
Results from TREOCAPA‑LT are planned for open access publication in line with funder requirements.